

Special Issue

Botulinum Toxins in Lower-Urinary-Tract Diseases and Dysfunctions

Message from the Guest Editors

The first clinical use of botulinum toxin A was in the late 1970s when an ophthalmologist, Dr. Alan Scott, studied its effects on strabismus. Ten years later, the first commercially available botulinum toxin, Oculinum, was FDA-approved to treat strabismus and blepharospasm. Oculinum was later renamed Botox in 1992. Since then, the indications for Botox have expanded to include cervical dystonia, chronic migraine, hyperhidrosis, spasticity, and certain lower-urinary-tract diseases. In addition to the FDA-approved indications for the treatment of lower-urinary-tract dysfunction with Botox, the literature regarding urologic applications of botulinum toxin also includes conditions such as benign prostatic hypertrophy, pelvic floor hypertonicity, and interstitial cystitis. This Special Issue of *Toxins* will include manuscripts describing the clinical experiences of botulinum toxin when treating the lower urinary tract.

Guest Editors

Dr. Karyn S. Eilber

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Dr. Jennifer T. Anger

Department of Urology, University of California, San Diego, CA, USA

Deadline for manuscript submissions

closed (31 October 2025)



Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.3
Indexed in PubMed



mdpi.com/si/229287

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)





Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.3
Indexed in PubMed



[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)



About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA,
USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).